Arcutis Biotherapeutics ARQT 深 滬
等待開盤 01-13 09:30:00 美东时间
26.78
-1.440
-5.10%
華盛通- 最 高28.10
- 今 開27.75
- 成交量 400.64万股
- 最 低 25.45
- 昨 收 28.22
- 總市值 32.14亿
- 52周最高 31.77
- 市盈率 靜 --
- 換手率 3.34%
- 52周最低 11.13
- 委 比 -5.21%
- 總股本 1.20亿
- 歷史最高 40.88
- 量 比 2.43
- 振 幅 9.39%
- 歷史最低 1.76
- 每 手 1
- 風險率 5.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
Arcutis Biotherapeutics announced its 2026 strategic priorities: Continued strong growth of ZORYVE® (roflumilast) with net product sales expected to reach $455–$470 million. Advancing ZORYVE's indication expansion with Phase 2 trials in vitiligo and hidradenitis suppurativa. Launching the clinical development program for ARQ-234 for atopic dermatitis. Transitioning to positive cash flows to accelerate ZORYVE growth and pipeline advancement.
01-12 13:00
Arcutis Biotherapeutics Appoints Amit Munshi as New Director
Arcutis Biotherapeutics ( ($ARQT) ) has provided an update. On December 3, 2025...
2025-12-09 05:44
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
Arcutis Biotherapeutics announced the appointment of Amit Munshi to its Board of Directors and the retirement of founding Board member Bhaskar Chaudhuri, who will continue as a consultant. Frank Watanabe, CEO, expressed confidence in Munshi's expertise in financing and strategic transactions to support the company's growth, including expanding the commercialization of ZORYVE and advancing its pipeline. Keith Leonard, chairman, thanked Chaudhuri f...
2025-12-08 21:00
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
2025-12-01 14:33
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Raises Price Target to $37
Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and raises the price target from $32 to $37.
2025-11-28 23:11
Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis
The U.S. FDA has accepted a sNDA from Arcutis Biotherapeutics (ARQT) for its Zoryve (roflumilast) cream for the treatment of plaque psoriasis in children ages two to five years old. The application ha...
2025-11-17 22:05
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) awarded 51,000 restricted stock units to six new employees under its 2022 Inducement Plan. The awards, granted on November 3, 2025, vest over four years, with 25% vesting annually. The company provided the information in compliance with Nasdaq Listing Rule 5635(c)(4). Arcutis focuses on创新 in免疫皮肤病学, with a portfolio of approved treatments for inflammatory skin diseases.</p>
2025-11-07 21:00
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
美股牛股 | CCJ飙升23%，与美国政府签署投资达800亿美元核能发电协议；诺基亚大涨22%
CCJ飙升23%，与美国政府签署投资达800亿美元核能发电协议；诺基亚大涨22%，公司获英伟达10亿美元股权投资；阿吉赛斯大涨22%，财报表现强劲并上调收入指引>>
2025-10-29 16:52
